The Global Omega-3 Market has witnessed continuous growth in the last few years and is projected to grow even further during the forecast period of 2024-2033. The assessment provides a 360° view and insights - outlining the key outcomes of the Omega-3 market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions.

Browse for Full Report at @ https://www.thebrainyinsights.com/report/omega-3-market-13063

Quick snapshot — market size & growth (summary of published ranges)

• Reported market size (recent estimates vary): different research houses report ~USD 2.4–8.0 billion for near-term market sizes (depends on whether they report omega-3 ingredients, supplements, or broader omega-3 uses). Representative sources: Market.us, SkyQuest/Grand View, Allied Market Research and The Business Research Company show numbers in this range. 

• Forecast/CAGR (typical reported range): ~7%–15% CAGR across forecasts (short windows and segmentation differences cause variation).

Bottom line: reports use different scopes (ingredients vs supplements vs full application set), so expect a spread. If you want a single consistent number, tell me which scope (ingredients, supplements, infant formula, aquaculture feed, or full market) and I’ll normalize.

Major companies — reference list (+ role / notes)

(These firms repeatedly appear as top global players in omega-3 ingredients, finished supplements, or tech suppliers.)

• dsm-firmenich (formerly DSM Nutritional Products) — major supplier of EPA/DHA ingredient, large global nutrition business.

• BASF SE — listed among top ingredient players and ingredient/formulation providers.

• Cargill, Inc. — supply chain & ingredient player (marine and algal supply partnerships).

• Aker BioMarine — specialty krill oil producer (consumer brand + ingredient supplier). 

• EPAX (Polaris / GC Rieber / EPAX) — Norway-based high-purity fish-oil concentrate manufacturer (EPA/DHA concentrates).

• Corbion / Cargill / ADM / Kerry / Croda — active either in algal oil, emulsifiers, encapsulation and ingredient supply for finished omega-3 products.

• Nordic Naturals, Nature’s Bounty, Orkla Health, Nutramax — prominent finished-goods brands in finished supplement market (regional leaders in retail).

Note on “values” (company-level omega-3 revenue): public market reports rarely publish precise company-level omega-3 revenue lines (companies usually report broader nutrition or lipids/ingredients segments). Paid intelligence (GOED report, proprietary market reports) or company investor filings are needed to estimate omega-3-specific revenues. GOED’s members and their sales data are a prime source for industry totals.

Recent developments

• Surging interest in non-marine omega-3 (algal) and krill for sustainability and vegan/vegetarian products — several press releases and market notes highlight algae-derived omega-3 growth and new capacity announcements. 

• Ingredient-level consolidation & large ingredient players listed as market leaders (dsm-firmenich, BASF, Cargill, ADM etc.) — many market reports list the same roster of lead players. 

• Growing commercial interest in infant-nutrition and pharma grade EPA/DHA (formulation & regulatory attention).

Drivers

• Rising consumer awareness of cardiovascular, cognitive and prenatal benefits → higher supplement demand.

• Plant-based & sustainability demand driving algal-oil investment (brand and ingredient side).

• Growth in infant nutrition, functional foods, pet food and aquaculture feed applications.  

Restraints

• Price volatility & raw material constraints for fish-oil feedstock (wild fish supply & fishing quotas).

• Regulatory scrutiny and label/health-claim constraints (especially for pharma/infant segments). 

• Premium price of algal/krill oil vs conventional fish oil can limit faster adoption in price-sensitive categories.

Regional segmentation analysis

• North America: large share of finished supplements market (high per-capita supplement consumption; U.S. leads).

• Europe: strong demand for high-purity and sustainable omega-3s; home to many ingredient producers (Norway, Netherlands).

• Asia-Pacific: fastest growth in many reports (infant nutrition, functional foods, rising middle class).

• Rest of World (LatAm, MEA): smaller but growing shares; local suppliers and brands present.

Emerging trends

• Algal-derived EPA/DHA scaling (targets vegan consumers and infant formula use). 

• Higher-purity EPA products and targeted dosing (EPA-first formulations for specific heart/mental health claims). 

• Encapsulation & delivery tech to improve oxidative stability and mask fishy taste (opportunities for ingredient/formulation players).

Top use cases

1. Dietary supplements (retail softgels, emulsions). 

2. Infant nutrition and maternal health formulations. 

3. Pharmaceutical / prescription omega-3 products (e.g., concentrated EPA for specific indications).

4. Functional foods & beverages, pet food, aquaculture feed (industry applications).

Major challenges

• Sourcing & sustainability pressures (responsible fisheries, certification).

• Oxidation & shelf-life issues require advanced formulation/packaging — technical barrier.

• Fragmented finished-goods market (many small brands) vs. concentrated ingredient suppliers — complicates channel dynamics.

Attractive opportunities

• Scale-up of algal oil for infant nutrition and vegan-label products (higher margins, premium positioning).

• Encapsulation & stabilization technologies for value-added finished products.

• B2B partnerships between ingredient makers and big FMCG/infant formula firms for secure supply chains.

Key factors of market expansion

• Increasing consumer health awareness and aging populations.

• Regulatory approvals and accepted health claims (drive clinical adoption & pharma use).

• Investments in sustainable algal/krill production and improved supply chains.

Practical next steps I can do right now (pick one)

• (A) Build an Excel table: company | country | role (ingredient / krill / algal / finished brand) | public citation links.

• (B) Pull company public filings & press releases and estimate omega-3-specific revenue for a short list of companies you care about (e.g., dsm-firmenich, Aker BioMarine, EPAX, Cargill).

• (C) Produce a one-page slide or market brief normalized to one scope (choose: ingredients only or supplements only).

Tell me which option you want and I’ll produce it immediately (I can generate the Excel or slide in this session).